Panel Discussion: Evaluating What Big Pharma & Investors Want to See in Antigen-Specific Immune Tolerance to Understand the Evidence Needed to Unlock Partnership & Investment

Review current levels of pharma and investor engagement with antigen-specific approaches to identify what would strengthen confidence in the space and positioning the field to attract deeper investment going forward.

• Understand what Big Pharma considers a commercially attractive indication and how they come to this decision to inform biotechs of what steps can support successful commercialization
• Discussing the type of data and evidence pharma and investors have indicated they want to see to clarify the gap between what is currently available and what may be expected, and explore how early-stage programs can prepare for this
• Considering how indication choice and commercial viability factor into investment decisions, to weigh biological rationale against practical, market-driven considerations, and inform how programs might frame their own value proposition

Speakers:

Matthias Von Herrath

Vice President of Translational Medicine & Immunology

Eli Lilly & Co.

Aaron Winkler

Senior Scientific Director, Immune Tolerance Lead

Pfizer

Joshua Vieth

Senior Director of Research

Breakthrough T1D

Turner Jenkins

Managing Director, Beyond Celiac Investments

Beyond Celiac

Charlotte Fribert

Chief Executive Officer

Bonsai Biotherapeutics

Kevin White

Executive Director, Corporate Venture Capital

Boehringer Ingelheim